CompletedNCT00817336
D-serine and biomarkers in schizophrenia
About this title
Read the official source — NCT00817336Researchers compared D Serine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–64United States
Understand this study
What did researchers investigate?
Researchers compared D Serine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- OrangeburgSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJune 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 16
- Sponsor
- Nathan Kline Institute for Psychiatric Research
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT00817336
- Official title
Show the full official title
Effect of an NMDA-based Intervention on Biomarker Measures of Cognitive Dysfunction in Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Orangeburg
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared D Serine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Nathan Kline Institute for Psychiatric Research, a research institute.
Did this study involve medication?
Yes. The study involved medication, including D Serine and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia